ArticleDiscover oncology2026
Integrative network pharmacology and in vitro validation reveal the mechanisms by which Apigenin reverses MET-TKI resistance in non-small cell lung cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oxyresveratrol Suppresses EGF-Induced AKT Phosphorylation and Reduces Cellular Fitness While Promoting Apoptosis in EGFR-Wild-Type Non-Small Cell Lung Cancer Cells Under EGF Stimulation.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to elucidate the molecular mechanisms by which Apigenin (APG) reverses MET-TKI resistance in non-small cell lung cancer (NSCLC).
methodsNetwork pharmacology and molecular docking were used to identify potential targets and signaling pathways of APG. Functional enrichment and protein-protein interaction analyses were integrated with in vitro validation, including CCK-8, wound healing, flow cytometry, and Western blot assays.
resultsKey hub genes such as MET, IGF1R, and PTGS2 were identified, primarily enriched in the PI3K/AKT and MAPK pathways. APG inhibited cell proliferation and migration, enhanced apoptosis, and reduced phosphorylation of MET and AKT in MET-TKI-resistant EBC-1-TepR cells.
conclusionThis study provides systematic evidence by integrating computational approaches with experimental methods, revealing that APG can regulate multiple targets related to drug resistance and inhibit the MET/PI3K/AKT signaling pathway. This indicates that APG can reverse acquired MET-TKI resistance in non-small cell lung cancer by targeting the core recovery pathways within the tumor. It offers a novel combination strategy for adjuvant treatment to overcome MET-TKI resistance in NSCLC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.